We’re joined by Toni Choueiri, MD, and Brian Shuch, MD, to

discuss several studies on the use of belzutifan alone and in combination withother treatments in patients with early and late-stage renal cancer, as well aspatients with Von Hippel-Lindau syndrome and advanced sporadic RCC. Dr. Shuchis the director of the University of California, Los Angeles’s Kidney CancerProgram and is the Alvin & Carrie Meinhardt Endowed Chair in Kidney CancerResearch. Dr. Choueiri is the director of Dana-Farber Cancer Institute’s LankCenter for Genitourinary Oncology, and serves as medical director ofDana-Farber’s International Strategic Initiatives.